Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder

Next Previous
Trial Profile

Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Pharmacokinetics; Proof of concept
  • Acronyms PRISMA-1
  • Sponsors Rovi

Most Recent Events

  • 12 Jul 2016 Results published in the International Clinical Psychopharmacology
  • 26 Jun 2015 According to a ROVI media release, results of this study were presented at the 12th European Association for Clinical Pharmacology and Therapeutics (EACPT) Congress, 2015.
  • 26 Jun 2015 Results published in the ROVI Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top